93 related articles for article (PubMed ID: 16771948)
1. A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C.
Krawitt EL; Gordon SR; Grace ND; Ashikaga T; Ray MA; Palmer M; Yarze JC; Moskowitz S;
Am J Gastroenterol; 2006 Jun; 101(6):1268-73. PubMed ID: 16771948
[TBL] [Abstract][Full Text] [Related]
2. Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.
Younossi ZM; McCullough AC; Barnes DS; Post A; Ong JP; O'Shea R; Martin LM; Bringman D; Farmer D; Levinthal G; Mullen KD; Carey WD; Tavill AS; Ferguson R; Gramlich T
Dig Dis Sci; 2005 May; 50(5):970-5. PubMed ID: 15906777
[TBL] [Abstract][Full Text] [Related]
3. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
[TBL] [Abstract][Full Text] [Related]
4. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.
Foster GR
Drugs; 2010; 70(2):147-65. PubMed ID: 20108989
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients.
Crespo M; Sauleda S; Esteban JI; Juarez A; Ribera E; Andreu AL; Falco V; Quer J; Ocaña I; Ruiz I; Buti M; Pahissa A; Esteban R; Guardia J
J Viral Hepat; 2007 Apr; 14(4):228-38. PubMed ID: 17381714
[TBL] [Abstract][Full Text] [Related]
6. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.
Hasan F; Asker H; Al-Khaldi J; Siddique I; Al-Ajmi M; Owaid S; Varghese R; Al-Nakib B
Am J Gastroenterol; 2004 Sep; 99(9):1733-7. PubMed ID: 15330911
[TBL] [Abstract][Full Text] [Related]
7. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.
Abergel A; Hezode C; Leroy V; Barange K; Bronowicki JP; Tran A; Alric L; Castera L; Bernard PH; Henquell C; Lafeuille H; Ughetto S; Darcha C; Chevallier M; Martineau N; Dubost S; Randl K; Dhumeaux D; Bommelaer G; Bonny C;
J Viral Hepat; 2006 Dec; 13(12):811-20. PubMed ID: 17109680
[TBL] [Abstract][Full Text] [Related]
8. Weekly pegylated interferon alpha-2b vs daily interferon a-2b versus standard regimen of interferon a-2b in the treatment of patients with chronic hepatitis C virus infection.
Horsmans Y; Colle I; Van Vlierberghe H; Langlet P; Adler M; Bourgeois N; Brenard R; Michielsen P; Goossens A; Bruckers L;
Acta Gastroenterol Belg; 2008; 71(3):293-7. PubMed ID: 19198574
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of pegylated interferon alpha 2b and ribavirin in chronic hepatitis C--a report from eastern India.
Ray G; Pal S; Nayyar I; Dey S
Trop Gastroenterol; 2007; 28(3):109-12. PubMed ID: 18383998
[TBL] [Abstract][Full Text] [Related]
10. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
11. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.
Buti M; Sanchez-Avila F; Lurie Y; Stalgis C; Valdés A; Martell M; Esteban R
Hepatology; 2002 Apr; 35(4):930-6. PubMed ID: 11915041
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.
Meyer-Wyss B; Rich P; Egger H; Helbling B; Müllhaupt B; Rammert C; Gonvers JJ; Oneta C; Criblez D; Rossi L; Borovicka J; Meyenberger C; Arn M; Renner EL;
J Viral Hepat; 2006 Jul; 13(7):457-65. PubMed ID: 16792539
[TBL] [Abstract][Full Text] [Related]
14. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
[TBL] [Abstract][Full Text] [Related]
15. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
Tsubota A; Arase Y; Suzuki F; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
J Gastroenterol; 2004; 39(2):155-61. PubMed ID: 15069622
[TBL] [Abstract][Full Text] [Related]
16. Sustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatment.
Mathew A; Peiffer LP; Rhoades K; McGarrity T
Dig Dis Sci; 2006 Nov; 51(11):1956-61. PubMed ID: 17004124
[TBL] [Abstract][Full Text] [Related]
17. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.
Shiffman ML; Ghany MG; Morgan TR; Wright EC; Everson GT; Lindsay KL; Lok AS; Bonkovsky HL; Di Bisceglie AM; Lee WM; Dienstag JL; Gretch DR
Gastroenterology; 2007 Jan; 132(1):103-12. PubMed ID: 17241864
[TBL] [Abstract][Full Text] [Related]
18. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
McHutchison J; Sulkowski M
J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
[TBL] [Abstract][Full Text] [Related]
19. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4.
Alfaleh FZ; Hadad Q; Khuroo MS; Aljumah A; Algamedi A; Alashgar H; Al-Ahdal MN; Mayet I; Khan MQ; Kessie G
Liver Int; 2004 Dec; 24(6):568-74. PubMed ID: 15566506
[TBL] [Abstract][Full Text] [Related]
20. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
